Daozhong Jin

Daozhong Jin

Auto-generated profile, based on publicly available information

Daozhong Jin

Center for Neuroscience and Pain Research, Department of Anesthesiology and Perioperative Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Brain Research
Verified
Journal Article
Closed access
DJDao-Zhong Jin
Dao-Zhong Jin
BXBing Xue
Bing Xue
LMLi-Min Mao
Li-Min Mao
JWJohn Q Wang
John Q Wang

2 September 2025 in Science Signaling
Verified
Journal Article
Closed access
DJDaozhong Jin
Daozhong Jin
HCHong Chen
Hong Chen
MZMeng-Hua Zhou
Meng-Hua Zhou
YHYuying Huang
Yuying Huang
SCShao-Rui Chen
Shao-Rui Chen
HPHui-Lin Pan
Hui-Lin Pan
Opioids relieve pain by activating μ-opioid receptors (MORs), which inhibit communication between pain-sensing neurons (nociceptors) and the spinal cord. However, prolonged opioid use can paradoxically lead to increased pain sensitivity (hyperalgesia) and reduced analgesic efficacy (tolerance), partly because of the activation of NMDA-type glutamate receptors (NMDARs) at the central terminals of primary sensory neurons in the spinal cord. Here, we identified a critical role for the G protein Gα q in this paradox. Pharmacological inhibition of Gα q in rats reversed morphine-induced increases in NMDAR phosphorylation, synaptic trafficking, and activity at sensory neuron terminals and reduced morphine-induced excitatory nociceptive input to spinal dorsal horn neurons. Morphine enhanced Gα q coupling specifically to metabotropic glutamate receptor 5 (mGluR5) dimers in the spinal cord. Furthermore, targeted knockdown of Gα q in dorsal root ganglion neurons in mice normalized NMDAR-related changes and prevented NMDAR-mediated synaptic potentiation triggered by MOR activation. In addition, either pharmacological or genetic disruption of Gα q signaling enhanced morphine’s analgesic effects while reducing hyperalgesia and tolerance. These findings reveal that Gα q signaling contributes to opioid-induced NMDAR hyperactivity at nociceptor central terminals by promoting MOR-mGluR5 cross-talk. Targeting this pathway may improve the safety and efficacy of opioid-based pain management.

25 August 2026 in Science Signaling
Verified
Journal Article
Closed access
DJDaozhong Jin
Daozhong Jin
HCHong Chen
Hong Chen
YHYuying Huang
Yuying Huang
SCShao-Rui Chen
Shao-Rui Chen
HPHui-Lin Pan
Hui-Lin Pan
Sustained hyperactivity of synaptic NMDA receptors (NMDARs) in the spinal dorsal horn is a hallmark of chronic neuropathic pain. Here, we identified the kinase BRAF as a critical regulator of this process. Spinal nerve injury in rats induced the translocation of BRAF from the dorsal root ganglion (DRG) to spinal cord synaptosomes, which was associated with enhanced phosphorylation of the downstream kinases MEK and ERK. In addition, spinal cord injury increased the interaction between NMDARs and BRAF/MEK/ERK in spinal cord samples from rats and humans. Pharmacological inhibition or genetic ablation of BRAF in mouse DRG neurons reversed nerve injury–induced NMDAR phosphorylation, synaptic trafficking, and presynaptic and postsynaptic hyperactivity in the spinal dorsal horn. Furthermore, whereas pain hypersensitivity persisted in wild-type mice after nerve injury, it was transient and less severe in mice that either lacked BRAF in DRG neurons or were treated with BRAF pathway inhibitors. Conversely, expressing a constitutively active BRAF mutant in DRG neurons induced sustained nociceptive hypersensitivity, which was blocked by NMDAR antagonists, gabapentin, or an α2δ-1 C-terminal-interfering peptide. This was accompanied by increased NMDAR phosphorylation and enhanced pre- and postsynaptic activity in the spinal cord. These findings reveal that BRAF in sensory neurons promotes neuropathic pain by enhancing NMDAR phosphorylation and transsynaptic hyperactivity and suggest that BRAF inhibitors might be repurposed to treat neuropathic pain.